Herzatec

Herzatec is a prescription medication that contains the active ingredient ramipril, an angiotensin‑converting enzyme (ACE) inhibitor. While the specific strength and dosage form are not detailed in the available product information, Herzatec is marketed in the European Union for oral administration. It belongs to the therapeutic class of antihypertensives and is used under medical supervision to manage several cardiovascular conditions, including hypertension and heart failure.

Herzatec (ramipril) is indicated for several cardiovascular and renal conditions as determined by a healthcare professional.

- Hypertension (high blood pressure) - Chronic heart failure - Post‑myocardial infarction management to reduce mortality risk - Diabetic nephropathy to slow renal disease progression - Left ventricular dysfunction following myocardial injury

Adverse reactions to Herzatec can vary in frequency and severity.

Common: - Persistent dry cough - Dizziness or light‑headedness, especially after standing - Headache - Fatigue or weakness - Mild hypotension - Elevated blood potassium levels (hyperkalaemia)

Serious: - Angioedema affecting face, lips, tongue, or airway - Severe hypotension leading to syncope - Acute renal impairment or failure - Neutropenia or agranulocytosis - Hepatic dysfunction with jaundice

Before starting Herzatec, patients should discuss their medical history with a clinician.

- Assess renal function; dose adjustment may be needed in impairment. - Monitor serum electrolytes, especially potassium, during therapy. - Use caution in patients with hepatic disease. - Pregnancy and lactation are contraindicated unless benefits outweigh risks. - Elderly patients may be more sensitive to hypotensive effects. - Concurrent use with diuretics may increase risk of volume depletion. - Regular blood pressure monitoring is essential to avoid excessive lowering.

Herzatec can interact with several medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Potassium‑sparing diuretics or supplements (risk of hyperkalaemia) - Aliskiren in patients with diabetes or renal impairment - Other ACE inhibitors or ARBs (additive blood‑pressure effect) - Lithium (increased lithium toxicity) - NSAIDs (may blunt antihypertensive effect and affect renal function)

Use with caution: - Loop or thiazide diuretics (monitor for hypotension and electrolyte shifts) - Beta‑blockers (enhanced bradycardia risk) - Rifampin (may reduce ramipril plasma levels) - Anticoagulants (monitor for bleeding if blood pressure falls dramatically) - Antidiabetic agents (adjust dose if blood glucose changes)